Lilly Sees Positive Results With Next-Gen Alzheimer’s Drug Donanemab
Patients Saw Less Cognitive, Functional Decline In Phase II Trial
Executive Summary
Lilly reported positive results from a Phase II pivotal trial of donanemab, which targets a modified form of beta-amyloid called N3pG, and has a second pivotal Phase II study under way.
You may also be interested in...
Keeping Track: US FDA Issues Alzheimer’s Breakthrough Designations, Arimoclomol CRL, Rinvoq Delays
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Lilly’s Donanemab Could Be A Near-Term Aduhelm Competitor
Lilly said it will seek accelerated approval in the US based on Phase II data for its amyloid-clearing antibody, potentially narrowing Biogen/Eisai’s newly approved therapy Aduhelm’s time on the market as the only disease-modifying Alzheimer’s drug.
Other Sources Fund Early-Stage Alzheimer’s Research As Pharma Favors Later Stages
New data show that early-stage Alzheimer’s trials increasingly are sponsored by government and nonprofit organizations, while another review illustrates diversification of the clinical pipeline.